Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels
Abstract Background Aldosterone is elevated in chronic kidney disease (CKD) and may be involved in hypertension. Surprisingly, the determinants of the plasma aldosterone concentration (PAC) and its role in hypertension are not well studied in CKD. Therefore, we studied the determinants of aldosteron...
Main Authors: | Christina M. Gant, Gozewijn D. Laverman, Liffert Vogt, Maartje C. J. Slagman, Hiddo J. L. Heerspink, Femke Waanders, Marc H. Hemmelder, Gerjan Navis, Holland Nephrology Study (HONEST) Network |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-12-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-017-0789-x |
Similar Items
-
Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?
by: Gozewijn D Laverman, et al.
Published: (2002-12-01) -
Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, Gitelman syndrome and Bartter syndrome
by: Wangna Tang, et al.
Published: (2022-02-01) -
Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunities
by: C. M. Gant, et al.
Published: (2023-08-01) -
The renin angiotensin aldosterone system and COVID-19
by: Hadeel A. Alsufyani, et al.
Published: (2020-08-01) -
The potential role of RAAS-related hsa_circ_0122153 and hsa_circ_0025088 in essential hypertension
by: Xin He, et al.
Published: (2021-11-01)